Key statistics
On Thursday, Rhythm Pharmaceuticals Inc (RYTM:NMQ) closed at 59.03, -13.93% below its 52-week high of 68.58, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 59.40 |
---|---|
High | 60.32 |
Low | 58.00 |
Bid | 56.88 |
Offer | 60.88 |
Previous close | 59.36 |
Average volume | 687.21k |
---|---|
Shares outstanding | 61.46m |
Free float | 57.57m |
P/E (TTM) | -- |
Market cap | 3.65bn USD |
EPS (TTM) | -4.31 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
- Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
- Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
- Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
More ▼